Back to discover
Disease

Reperfusion Injury

Late-stage therapeutic developmentEmerging researchRising momentum
7
Publications
19
Clinical trials
3
Related conditions
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets.

Research2024-01-08Signal transduction and targeted therapy

Ferroptosis: past, present and future.

Research2020-02-03Cell death & disease

NAD<sup>+</sup> homeostasis in renal health and disease.

Research2019-10-31Nature reviews. Nephrology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Clinical trials

18 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
9
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Research activity

7 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20202024
Most influential

Ferroptosis: past, present and future.

Cell death & disease · 2020 · 2,924 cites

Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets.

Signal transduction and targeted therapy · 2024 · 390 cites

NAD<sup>+</sup> homeostasis in renal health and disease.

Nature reviews. Nephrology · 2020 · 236 cites
Recent publications
Major themes8
  • Reperfusion Injury4
  • Brain Ischemia2
  • Stroke2
  • Carcinoma, Renal Cell1
  • Cognitive Dysfunction1
  • Ischemic Stroke1
  • Kidney Diseases1
  • Kidney Neoplasms1
Leading journals6
  • International journal of molecular sciences2
  • Cell death & disease1
  • Molecular neurobiology1
  • Nature reviews. Nephrology1
  • Neuroscience bulletin1
  • Signal transduction and targeted therapy1
Leading researchers8
  • Battaglia M1
  • Cao F1
  • Chen Y1
  • Crocetto F1
  • Deng B1
  • Ditonno P1
  • Du H1
  • Duan H1
Affiliations (unnormalised)6
  • Affiliated Drum Tower Hospital1
  • Affiliated Qiqihar Hospital1
  • Basic medical school1
  • Center for Vascular Biology Research and Department of Medicine1
  • Clinical Medical College1
  • Clinical Municipal Hospital "dr. G. Curteanu" Oradea1

Related conditions

3 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Reperfusion injury is tissue damage that occurs when blood flow is restored after a period of ischemia. The restoration of perfusion can paradoxically worsen functional, metabolic, or structural injury in the affected tissue.

Causes

It is caused by reperfusion following ischemia. The grounding supports ischemia-reperfusion as the defining setting, but does not identify additional primary causes beyond the ischemic event and subsequent restoration of blood flow.

Pathophysiology

The literature grounding links reperfusion injury to multiple injury pathways, including apoptosis, cell death, oxidative stress, inflammatory responses, and neuroinflammation in cerebral ischemia. It also supports involvement of ferroptosis, characterized by iron-dependent lipid peroxidation and reduced antioxidant capacity, as well as signaling networks such as Wnt and complement activation in kidney injury and transplantation settings.

Risk factors

The main risk factor supported by the grounding is prior ischemia followed by reperfusion. The reviewed literature also indicates higher relevance in settings such as ischemic stroke, kidney transplantation, and acute kidney injury, but does not support additional general risk factors.

Current standard of care

The grounding supports treatment at the modality and drug-class level only indirectly, mainly through reperfusion-based interventions and investigational neuroprotective or organ-protective strategies. Reported therapeutic areas include thrombolysis and thrombectomy in ischemic stroke, and experimental or clinical attempts targeting neuroinflammation, complement, Wnt-related signaling, ferroptosis, and NAD+ homeostasis. No specific standard drug regimen is supported by the supplied material.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.